Amgen maintained at peer perform by Bear Stearns

Bear Stearns analyst Mark Schoenebaum kept Amgen Inc. at peer perform. Johnson & Johnson is suing Amgen over the company's bundling of Aranesp with Neulasta/Neupogen. Bear Stearns does not expect a preliminary injunction to be granted and expects a decision in weeks or months. A worst-case scenario could lower 2007 earnings per share by $0.15, according to the analyst. Shares of the Thousand Oaks, Calif.-based biotechnology were up 5 cents, or 0.07%, at $66.94 on volume of 11,568,538 shares versus the three-month running average of 9,078,740 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.